Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide. The company operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment provides magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound systems. The Diagnostics segment offers in-vitro diagnostic products and services to healthcare providers in laboratory, molecular and point-of-care diagnostics; and workflow solutions for laboratories and informatics products. The Varian segment provides cancer care technologies, and solutions and services to oncology departments in hospitals and clinics; and technology-enabled optimized workflows, clinical services and consulting capabilities, and digital solutions and applications for managing treatment and therapy. The Advanced Therapies segment offers products that are designed to support image-guided minimally invasive treatments in various areas, such as cardiology, interventional radiology, and surgery; and angiography systems and mobile C-arms, including a robotic-assisted platform for endovascular coronary and peripheral vascular interventions. It also provides equipment performance management, clinical education and e-learning, asset management, and managed departmental services for laboratories and healthcare facilities, as well as consulting and digital health services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.
Revenue of Siemens Healthineers AG (SHL.DE)
Revenue in 2024 (TTM): $23.42 B
According to Siemens Healthineers AG's latest financial reports the company's current revenue (TTM) is $23.42 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Siemens Healthineers AG
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2024 | $23.42 B | $8.87 B | $4.43 B | $2.64 B | $2.03 B |
| 2023 | $22.71 B | $8.07 B | $3.96 B | $2.02 B | $1.58 B |
| 2022 | $22.74 B | $8.52 B | $4.46 B | $2.93 B | $2.13 B |
| 2021 | $18.85 B | $7.28 B | $3.69 B | $2.52 B | $1.81 B |
| 2020 | $15.15 B | $5.84 B | $2.98 B | $2.05 B | $1.48 B |
| 2019 | $15.21 B | $6.07 B | $3.07 B | $2.3 B | $1.64 B |
| 2018 | $14.07 B | $5.73 B | $2.65 B | $1.88 B | $1.33 B |
| 2017 | $14.45 B | $6.04 B | $2.94 B | $2.14 B | $1.49 B |
| 2016 | $14.19 B | $5.73 B | $2.85 B | $2.01 B | $1.37 B |
| 2015 | $13.55 B | $5.31 B | $2.67 B | $1.97 B | $1.34 B |